InSpace Accelerated Rehabilitation Study (iAccelerate)

An Assessment of Two Accelerated Rehabilitation Programs for Use With the InSpaceTM Subacromial Tissue Spacer System in the Treatment of Full-thickness Massive, Irreparable Rotator Cuff Tears

This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.

Study Overview

• Status: Recruiting
• Conditions: Rotator Cuff Tears
• Intervention / Treatment: Device: InSpace Subacromial Tissue Spacer

Detailed Description

Study Objectives:

Primary:

• To evaluate clinical outcomes of both a formalized or an at-home rehabilitation program when used in conjunction with the InSpace device as compared to the corresponding InSpace Pivotal study results.

• To demonstrate consistency of each intervention group with the corresponding historical control study results.
• To demonstrate that comparable clinical outcomes can be achieved for each intervention group.

Secondary:

• Change in clinical outcomes compared to baseline.

• Study Type: Interventional
• Enrollment (Estimated): 160
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Hayley Taylor, MS; Phone Number: 805-705-4206; Email: hayley.taylor@stryker.com

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85023
      • Recruiting
      • Musculoskeletal-Orthopedic Research and Education Foundation
      • Contact: Wafa Mohsin; Email: wafa.mohsin@more-foundation.org
      • Principal Investigator: Michael Amini, MD
      • Sub-Investigator: Michael Rose, MD
      • Sub-Investigator: John Brown, MD
  • Colorado
    • Englewood, Colorado, United States, 80112
      • Recruiting
      • Steadman Hawkins Clinic Denver
      • Principal Investigator: James Genuario
      • Sub-Investigator: Brayden Mayer
      • Sub-Investigator: Martin Boublik
      • Sub-Investigator: Thomas Noonan
      • Sub-Investigator: Adam Seidl
      • Contact: Lauren Heylmun; Email: LAUREN.HEYLMUN@CUANSCHUTZ.EDU
  • Florida
    • Fort Lauderdale, Florida, United States, 33308
      • Recruiting
      • Holy Cross Hospital
      • Contact: David Henderson; Email: David.Henderson002@holy-cross.com
      • Principal Investigator: Ross Wodika, MD
    • West Palm Beach, Florida, United States, 33407
      • Recruiting
      • Paley Orthopaedics & Spine
      • Principal Investigator: Jonathan Levy, MD
      • Contact: Janice Schuck; Email: janice.schuck@tenehealth.com
  • Georgia
    • Atlanta, Georgia, United States, 30329
      • Recruiting
      • Emory University
      • Contact: Isabelle Vernon; Email: isabelle.m.vernon@emory.edu
      • Principal Investigator: Eric Wagner, MD
      • Sub-Investigator: Michael Gottschalk, MD
  • Illinois
    • Chicago, Illinois, United States, 60612
      • Recruiting
      • Rush University Medical Center
      • Sub-Investigator: Gregory Nicholson, MD
      • Sub-Investigator: Brian Cole, MD
      • Contact: Kavita Ahuja; Email: kavita.ahuja@rushortho.com
      • Contact: Mukesh Ahuja; Email: Mukesh.Ahuja@rushortho.com
      • Principal Investigator: Nikhil Verma, MD
      • Sub-Investigator: Grant Garrigues, MD
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Recruiting
      • Mayo Clinic
      • Principal Investigator: Joaquin Sanchez Sotelo
      • Contact: Lindsey Hobbs; Email: hobbs.lindsey@mayo.edu
  • New York
    • New York, New York, United States, 10021
      • Recruiting
      • Hospital for Special Surgery
      • Contact: Anthony Finocchiaro; Email: finocchiaroa@hss.edu
      • Principal Investigator: Michael Fu, MD
      • Sub-Investigator: Joshua Dines, MD
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19107
      • Recruiting
      • The Rothman Institute
      • Principal Investigator: Joseph Abboud, MD
      • Contact: Thema Nicholson; Email: thema.nicholson@rothmanortho.com
  • Texas
    • San Antonio, Texas, United States, 78258
      • Recruiting
      • TSAOG Orthopaedics & Spine
      • Principal Investigator: Robert Hartzler, MD
      • Sub-Investigator: Lane Naugher, MD
      • Sub-Investigator: Sergio Viroslav, MD
      • Contact: Amanda Strickland; Email: astrickland@brioresearch.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Subjects MUST meet ALL the following criteria to be included in the study:

• The subject has signed the IRB approved Informed Consent Form (ICF) specific to this study prior to enrollment
• Is male or female ≥ sixty-five (65) years of age

• Positive diagnostic imaging by MRI within 9 months of enrollment of the index shoulder indicating a full thickness MRCT:

  • Measuring ≥ 5 cm in diameter
  • Involving ≥ two tendons
• Functional deltoid muscle and preserved passive range of motion on physical examination
• Documented VAS score > 30 mm pain

• Failed non-operative treatment of at least 3 months from the initial treatment to include one or more of the following:

  • Oral analgesics
  • Anti-inflammatory medication (e.g., ibuprofen, naproxen)
  • Corticosteroid injection(s)
  • Physical therapy
  • Activity modification
  • Rest (sling used)
• Must be able to read and understand the approved Informed Consent Form (written and oral)
• Must be in general good health (as determined by the Investigator) based on screening assessments and medical history
• Must be independent, ambulatory, and can comply with all post-operative evaluations, visits, and electronic database collection

Intra-operative Inclusion Criteria

Subjects MUST meet the following criteria to be randomized in the study:

• Full thickness tear
• Tear size ≥ 5 cm in diameter
• Tear involving ≥ two tendons

Exclusion Criteria:

Subjects will be excluded from the study, if they meet ANY of the following individual exclusion criteria:

• Known allergy to the device material (copolymer of PLA (poly (lactic acid) and -ε-caprolactone)

• Evidence of the following conditions:

  • Severe gleno-humeral or acromio-humeral arthritis
  • Full thickness cartilage loss as seen on MRI
  • History within the past 5 years of anterior or posterior shoulder subluxation or dislocation as determined by history, examination, or radiographic findings
  • Pre-existing deltoid defect or deltoid palsy
  • Major joint trauma, infection, or necrosis
  • Partial thickness tears of the supraspinatus
  • Fully reparable rotator cuff tear [Tear of less than 5 cm in diameter (or < 4 cm2) with retractable tendon that can be fully repaired]
  • Known neurovascular compromise
  • Complete deltoid muscle palsy
  • Traumatic muscle tears of the pectoralis or deltoid

• The subject requires concomitant:

  • Subscapularis repair
  • Labral repair of any type
  • Biceps tenodesis
• Previous surgery of the index shoulder in the past 1 year, excluding diagnostic arthroscopy
• The subject's condition is bilateral and rotator cuff repair is scheduled or to be scheduled over the course of this study for the contra lateral shoulder
• Major medical condition that could affect quality of life and influence the results of the study (e.g., rheumatoid arthritis)
• The subject has documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment
• The subject's condition represents a worker's compensation case
• The subject is currently involved in a health-related litigation procedure
• Females of child-bearing potential who are pregnant or plan to become pregnant.
• Concurrent participation in an investigational clinical study one month prior to enrollment or during the entire study period
• The subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.), to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant to follow-up
• The subject is receiving prescription narcotic pain medication for conditions unrelated to the index shoulder condition
• The subject currently has an acute infection in the area surrounding the surgical site.
• Baseline WORC score less than 420

Intra-operative Exclusion Criteria:

Subjects will not be randomized and will be terminated from the study if they meet ANY of the following individual intra-operative exclusion criteria:

• Rotator cuff is/presents with:

  • Fully reparable with adequate tissue and muscle quality (equivalent to Goutallier stage 1 or 2)
  • Partial thickness tear of the supraspinatus
  • Evidence of significant osteoarthritis

• The subject requires concomitant:

  • Subscapularis repair
  • Labral repair of any type
  • Biceps tenodesis
• Coracoacromial ligament functional deficiency or shoulder instability is identified

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group I; InSpace device + accelerated rehabilitation in a formalized program (FP)	Device: InSpace Subacromial Tissue Spacer; Rotator Cuff Tear Treatment
Experimental: Group II; InSpace device + accelerated rehabilitation in an at-home program (AHP)	Device: InSpace Subacromial Tissue Spacer; Rotator Cuff Tear Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in American Shoulder and Elbow (ASES) Score	This is a subject self-report questionnaire and Investigator assessment questionnaire. The subject portion collects information on activities of daily living (i.e., 10 questions). The Investigator assessment portion documents ROM (forward elevation/flexion, external rotation, internal rotation, cross-body adduction), signs, strength, and instability. ASES minimal clinical important difference (MCID) and substantial clinical benefit (SCB) have been previously described for the ASES score in patients undergoing rotator cuff repair as 11.1 and 17.5, respectively. Change in American Shoulder and Elbow Surgeons (ASES) Score will be expressed as the percentages demonstrating a minimal clinical important difference (MCID; ASES ≥ 11.1) and the substantial clinical benefit (SCB; ASES ≥ 17.5) in ASES from baseline at Month 12. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome).	Day 0 through Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Assessment	• Safety will be evaluated by type, frequency, severity, and relatedness of adverse events to study intervention at each follow-up visit through Month 24	Day 0 through Month 24
Change in Western Ontario Rotator Cuff (WORC) Score	Change in WORC Score from baseline. Minimum value: 2,100, Maximum value: 0 (with a lower score indicating a better outcome). This is a subject self-report questionnaire that is a disease-specific Quality of Life Measurement Tool specifically designed to evaluate quality of life in persons with pathology of the rotator cuff. It is comprised of 21 items in 5 domains (i.e., physical symptoms, sports and recreation, work, lifestyle, emotions).	Day 0 through Month 24
Change in Constant Score (CS) Outcome Score	Change in CS Outcome Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a self-reported questions as well as Investigator or designee performed assessment of the shoulder. The tool is divided into four subscales: pain, activities of daily living, strength and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder.	Day 0 through Month 24
Change in EuroQol 5-Dimensions Questionnaire (EQ-5D-5L) Score	Change in EQ-5D-5L Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a subject self-report questionnaire to measure health-related quality of life (HRQOL). It consists of 5 questions capturing the subject's current health across five dimensions (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). It also includes a numerical visual analogue scale (EQ-VAS).	Day 0 through Month 24
Change in Visual Analog Scale (VAS) Score	Change in VAS Score from baseline. This is a subject self-report questionnaire to measure pain. The patient marks on the line the point that they feel represents their perception of their current state. The amount of pain that a patient feels ranges across a continuum from none to an extreme amount of pain. (An extreme amount of pain would be considered a worse outcome)	Day 0 through Month 24
Change in Range of Motion (ROM) Score	Change in ROM Score from baseline. Minimum value: 0, Maximum value: 180 (with a higher score indicating a better outcome).	Day 0 through Month 24
Change in Single Assessment Numeric Evaluation (SANE) Score	Change in SANE from baseline. Minimum value: 0%, Maximum value: 100% (with 100% being normal). This is a subject self-report questionnaire to measure function. The patient marks on the line the point that they feel represents their perception of their current state of functional improvement. Example: "How would you rate your affected shoulder today as a percentage of normal (0% to 100% scale with 100% being normal)?"	Day 0 through Month 24
Patient's satisfaction with their procedure	Patient Satisfaction Score at Month 12 and Month 24. This is a single-question to evaluate the patients' current state of satisfaction. Responses are binary with Yes or No answers. ('Yes' would be considered a positive outcome)	Month 12 and Month 24
Costing	Costs associated with all visits	Day 0 through Month 24
Time to Recovery	Time to recovery by cumulative time between discharge and return to driving	Day 0 through Month 24
Analgesia Use	Analgesia use (drug and frequency)	Day 0 through Month 24

Collaborators and Investigators

• Sponsor: Stryker Endoscopy
• Investigators: Study Director: Colleen Roden, MS, Stryker Endoscopy

Study record dates

Study Major Dates

• Study Start (Actual): February 7, 2022
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): April 1, 2025

Study Registration Dates

• First Submitted: March 17, 2022
• First Submitted That Met QC Criteria: April 7, 2022
• First Posted (Actual): April 15, 2022

Study Record Updates

• Last Update Posted (Actual): March 15, 2024
• Last Update Submitted That Met QC Criteria: March 13, 2024
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries; Rupture; Shoulder Injuries; Tendon Injuries; Rotator Cuff Injuries
• Other Study ID Numbers: SYK-SM-2021-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No